-
Guggenheim Starts Context Therapeutics (CNTX) at Buy
-
Context Therapeutics (CNTX) PT Lowered to $4 at Piper Sandler
-
Citizens JMP Reiterates Market Outperform Rating on Context Therapeutics (CNTX)
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Context Therapeutics (CNTX) Appoint Dr. Karen Chagin as Chief Medical Officer
-
Citizens JMP shares updates on cancer treatment stocks
-
Context Therapeutics Inc. (CNTX) Tops Q1 EPS by 7c
-
Context Therapeutics (CNTX) Announces Chief Medical Officer Transition
-
Context Therapeutics (CNTX) Presents Preclinical and Translational Data for CT-95
-
William Blair Starts Context Therapeutics (CNTX) at Outperform
-
Citizens JMP Reiterates Market Outperform Rating on Context Therapeutics (CNTX)
-
Context Therapeutics (CNTX) Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
-
Context Therapeutics (CNTX) Appoints Andy Pasternak as Board Chair
-
JMP Securities Starts Context Therapeutics (CNTX) at Market Outperform
-
Context Therapeutics Inc. (CNTX) Misses Q3 EPS by 17c
-
Piper Sandler Reiterates Overweight Rating on Context Therapeutics (CNTX)
-
H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)
-
BioAtla (BCAB) and Context Therapeutics (CNTX) Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362
-
Piper Sandler Reiterates Overweight Rating on Context Therapeutics (CNTX)
-
Piper Sandler Reiterates Overweight Rating on Context Therapeutics (CNTX)
-
Context Therapeutics (CNTX) Appoints Karen Smith and Luke Walker to its Board
-
Context Therapeutics (CNTX) PT Raised to $6 at H.C. Wainwright
-
Context Therapeutics (CNTX) Appoints Claudio Dansky Ullmann as Chief Medical Officer
-
H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)
-
Context Therapeutics (CNTX) Acquires Phase 1-ready T cell Engager CT-95

